Weight is one of the commonest reasons women give for stopping a contraceptive, and the evidence behind that belief has always been thinner than the belief. A Danish nested case-control study came at it sideways, asking not whether contraception changes weight but whether women who had used it were more likely to later fill a prescription for semaglutide[1]. The related clinical questions are set out in four questions about contraception, one answered.
Every woman aged 12 to 49 in the Danish registers between 1996 and 2023 was eligible. Those who filled a first semaglutide prescription, with no prior glucose-lowering drug, became cases; each was matched to ten controls born the same year. That gave 22,694 cases and 229,640 controls, with a median age of 37.
Every contraception pattern was associated with later semaglutide use. Among women who had used a single type, adjusted hazard ratios ran from 1.42 (95% CI 1.34–1.51) for combined oral tablets to 1.63 (95% CI 1.46–1.82) for progestin-only intrauterine devices. Among those who had used two or more types, they ran from 1.64 (95% CI 1.47–1.82) to 2.11 (95% CI 1.97–2.25). Adjusting for BMI made these smaller without eliminating them, and the pattern held across age, education, income, parity and immigrant status.
The third explanation deserves more weight than it usually gets. Getting a contraceptive prescription means being in the health system. So does getting semaglutide. Any two prescriptions drawn from the same population will correlate somewhat for that reason alone, and a register study sees the prescriptions rather than the reasons behind them.
There is still something here for a reader deciding what to buy. A large share of the women starting these drugs arrive from a contraceptive prescription, which makes the interaction between the two a routine question rather than an edge case, and it is not one a checkout page will raise. The wider point that buyers carry more medical history than the marketing implies is documented in what else weight-drug users were already carrying, who is reaching these drugs at all in who the price filtered out, and what the whole market charges in what a GLP-1 actually costs.